KIT: A Protein Targeted for Cancer and Fibrosis (G3815)

Target Name: KIT

NCBI ID: G3815

Content of Review Report on KIT Target / Biomarker

KIT

KIT: A Protein Targeted for Cancer and Fibrosis

KIT (Tyrosine-protein kinase) is a protein that is expressed in various tissues and cell types in the human body. It is involved in the regulation of cell growth, differentiation, and survival. KIT has also been implicated in the development and progression of several diseases, including cancer. As a result, KIT has emerged as a potential drug target and biomarker for a variety of diseases.

The KIT protein is a tyrosine kinase, which means that it is involved in the regulation of protein tyrosination. This process involves the binding of a tyrosine molecule to a protein kinase, leading to the activation of the kinase and the phosphorylation of its catalytic residue. The tyrosine molecule is a small protein that is synthesized in the cell and is often modified to have a tyrosine tag, which allows it to interact with the protein kinase. The tyrosine-protein kinase is a protein that is composed of multiple subunits that are encoded by different genes.

KIT is involved in the regulation of cell growth and differentiation by controlling the cell cycle. It plays a role in the G1 phase of the cell cycle, which is the phase of growth and development when the cell prepares for cell division. During the G1 phase, KIT helps to regulate the production of mitogenic factors, such as the protein growth factor (PDGF), which is involved in the growth and development of cells.

KIT is also involved in the regulation of cell survival. It has been shown to play a role in the regulation of cell survival by promoting the production of apoptosis-associated protein (AP-1). AP-1 is a protein that is involved in the regulation of cell death, and it has been shown to be involved in the development of cancer. KIT has also been shown to promote the production of another protein called Bcl-2, which is involved in the regulation of apoptosis.

KIT has also been implicated in the development and progression of several diseases, including cancer. For example, it has been shown to be involved in the development of colon cancer by promoting the production of pro-inflammatory cytokines. It has also been shown to be involved in the development of liver cancer by promoting the production of angiogenesis-promoting factors.

In addition to its role in the development and progression of cancer, KIT has also been implicated in the regulation of a variety of other diseases. For example, it has been shown to play a role in the regulation of inflammation by promoting the production of pro-inflammatory cytokines. It has also been shown to play a role in the regulation of neurodegenerative diseases by promoting the production of neurotoxins.

As a result of its involvement in the regulation of cell growth, differentiation, and survival, KIT has emerged as a potential drug target for a variety of diseases. For example, it has been shown to be an effective target for cancer treatments by inhibiting its activity. Researchers have also developed compounds that can specifically target KIT and enhance its inhibition of cell growth and differentiation. These compounds have been shown to be effective in a variety of cancer models, including mouse models of breast, lung, and ovarian cancer.

In addition to its potential as a cancer treatment, KIT has also been shown to be a potential biomarker for several diseases. For example, it has been shown to be involved in the regulation of fibrosis, which is the process by which tissues become stiff and fibrotic. Researchers have shown that KIT plays a role in the regulation of fibrosis by promoting the production of extracellular matrix (ECM) components. This suggests that KIT may be a useful biomarker for

Protein Name: KIT Proto-oncogene, Receptor Tyrosine Kinase

Functions: Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1, SH2B2/APS and CBL. Activates the AKT1 signaling pathway by phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Activated KIT also transmits signals via GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3, STAT5A and STAT5B. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. KIT signaling is modulated by protein phosphatases, and by rapid internalization and degradation of the receptor. Activated KIT promotes phosphorylation of the protein phosphatases PTPN6/SHP-1 and PTPRU, and of the transcription factors STAT1, STAT3, STAT5A and STAT5B. Promotes phosphorylation of PIK3R1, CBL, CRK (isoform Crk-II), LYN, MAPK1/ERK2 and/or MAPK3/ERK1, PLCG1, SRC and SHC1

The "KIT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets